Immune privilege or inflammation? Insights into the Fas ligand enigma

被引:132
作者
O'Connell, J [1 ]
Houston, A
Bennett, MW
O'Sullivan, G
Shanahan, F
机构
[1] Natl Univ Ireland, Univ Hosp, Dept Med, Cork, Ireland
[2] Natl Univ Ireland, Mercy Hosp, Dept Surg, Cork, Ireland
基金
英国惠康基金;
关键词
D O I
10.1038/85395
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
引用
收藏
页码:271 / 274
页数:4
相关论文
共 42 条
[1]  
Arbuckle E, 2000, ONCOL REP, V7, P45
[2]  
Bennett MW, 1998, J IMMUNOL, V160, P5669
[3]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[4]  
Eberl LP, 1999, INT J CANCER, V81, P772, DOI 10.1002/(SICI)1097-0215(19990531)81:5<772::AID-IJC18>3.0.CO
[5]  
2-S
[6]   The role of FasL-induced apoptosis in immune privilege [J].
Griffith, TS ;
Ferguson, TA .
IMMUNOLOGY TODAY, 1997, 18 (05) :240-244
[7]   Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival [J].
Hohlbaum, AM ;
Moe, S ;
Marshak-Rothstein, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07) :1209-1219
[8]  
Ito Y, 2000, BRIT J CANCER, V82, P1211
[9]   Interleukin 1 and interleukin 1β converting enzyme (caspase 1) expression in the human colonic epithelial barrier.: Caspase 1 downregulation in colon cancer [J].
Jarry, A ;
Vallette, G ;
Cassagnau, E ;
Moreau, A ;
Bou-Hanna, C ;
Lemarre, P ;
Letessier, E ;
Le Neel, JC ;
Galmiche, JP ;
Laboisse, CL .
GUT, 1999, 45 (02) :246-251
[10]   Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction [J].
Kang, SM ;
Schneider, DB ;
Lin, ZH ;
Hanahan, D ;
Dichek, DA ;
Stock, PG ;
Baekkeskov, S .
NATURE MEDICINE, 1997, 3 (07) :738-743